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2280Background: Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal
cancer. Both drugs are believed to act via a p53-dependent apoptosis pathway. The TP53 gene is frequently
mutated in esophageal cancer.
Objective: To test the value of TP53 as a biomarker prognosing outcome in patients with neoadjuvantly treated
esophageal cancer.
Patients and Methods: The investigation included 36 patients with primary operable esophageal cancer who
were treated neoadjuvantly with cisplatin and fluorouracil. The TP53 genotype was assessed from paraffin-
embedded diagnostic tumor biopsies using a standardized gene-specific TP53 sequencing protocol (mark53
kit; mark53 Ltd, Vienna, Austria).
Results:Mutations in the TP53 genewere present in 50% of tumors. Two-year overall survival rates were 55.6%
in patients with a normal TP53marker status, comparedwith 16.7% in thosewith a mutant TP53 gene. In patients
with normal TP53, neoadjuvant treatment resulted in significant advantages in terms of tumor-associated survival
(P ¼ .0049) and overall survival (P ¼ .0304) compared with those with mutant TP53. The median tumor-
associated survival was 34.2 months for patients with normal TP53, compared with 8.9 months for those with
mutantTP53. The latter had a 3-fold higher risk of dying (hazard ratio, 3.01; 95% confidence interval, 1.359-6.86).
Conclusions: The biomarker TP53 divides esophageal cancer patients into 2 categories with markedly different
outcomes: patients with a normal TP53marker status may experience notable benefits from neoadjuvant chemo-
therapy with cisplatin/fluorouracil, whereas those with a mutant TP53marker status appear to be at risk for lack
of response. (J Thorac Cardiovasc Surg 2014;148:2280-6)See related commentary on pages 2286-7.In patients with esophageal cancer, fluorouracil and
cisplatin have been used as the standard preoperative
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The Journal of Thoracic and Cardiovascular Sura marginal survival benefit for preoperative chemotherapy
with cisplatin/fluorouracil compared with surgery alone
in patients with resectable esophageal cancer. Survival
appears to be most significantly improved in patients expe-
riencing complete histopathologic response.2,3 However,
complete response rarely occurs under this regimen (5%-
15%) and currently responders cannot be identified
before treatment. The use of more intensive regimens to
improve complete response rates appeared to be limited
by the concomitant increase in treatment-related morbidity
and mortality.4
Markers predicting response to chemotherapy would
greatly enhance the efficacy of treatment and simulta-
neously reduce chemotherapy-related risks by permitting
individualized preoperative treatment. No such predictive
markers have been established for esophageal cancer.
P53 has been suggested to play a crucial role in a patient’s
response to various chemotherapeutic regimens. Defective
TP53 has been considered a plausible reason for drug resis-
tance, thus permitting response prediction.5 Chemotherapy
drugs such as cisplatin and fluorouracil act by inducing
DNA damage. The latter is the strongest trigger for thegery c November 2014
Abbreviations and Acronyms
CR ¼ complete remission
CROSS ¼Neoadjuvant Chemoradiation Followed
by Surgery versus Surgery Alone for
Patients with Adenocarcinoma or
Squamous Cell Carcinoma of the
Esophagus
PANCHO ¼ p53-Adjusted Neoadjuvant
Chemotherapy for Potentially
Resectable Esophageal Cancer
PET ¼ positron emission tomography
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Sactivation of the TP53 gene. As a result p53 transactivates
genes of the apoptotic cascade resulting in programmed
cell death. However, because TP53 is the most frequently
mutated gene associated with cancer, this pathway is often
disrupted.6
We hypothesized that p53 mutation status may be useful
for prognosing outcome in patients with resectable esopha-
geal cancer treated with neoadjuvant chemotherapy. The
aim of the study was to evaluate the association of response
to neoadjuvant cisplatin/fluorouracil in patients with esoph-
ageal cancer stratified for the tumor’s TP53 status.
METHODS
Patients with primary operable esophageal cancer and treated by neoad-
juvant chemotherapy were included in this phase II biomarker study. From
August 2001 to May 2007, we identified 47 consecutive patients who
received neoadjuvant treatment at 2 institutions.
Neoadjuvant treatment consisted of 2 cycles of chemotherapy with
cisplatin 80 mg/m2 as an intravenous infusion over 4 hours on day 1, and
fluorouracil 1000 mg/m2 as a continuous infusion on day 1 and day 14 in
36 patients. The neoadjuvant regimen is based on the results of the United
Kingdom Medical Research Council esophageal cancer trial.7 Eleven pa-
tients who received a different treatment were excluded.
The study was approved by the local ethics committee and included
informed consent for DNA testing.
Staging was performed before and after neoadjuvant chemotherapy
to determine operability. Clinical staging included computed tomography
of the abdomen, chest, and neck; endoscopy/biopsy of the upper gastroin-
testinal tract; as well as a positron emission tomography (PET) scan in
some patients and bronchoscopy in patients with squamous cell carcinoma.
Computed tomography scans were used to determine the patients’
resectability and the tumor mass at initial staging and preoperative
restaging. Data from fluordeoxyglucose PET scans were available for 10
patients. The remaining patients had either no PET on the day of staging
and/or restaging. Thus we did not include this information in our analysis.
At restaging7patientshadcriteriaof inoperabilityafter neoadjuvant chemo-
therapy; local progressionwas seen in 4 patients who therefore had exploration
only.Denovodistantmetastaseswere detected in 3patientswhowere excluded
from surgery. Although these 7 patients had no complete tumor resection, they
were not excluded from survival analysis; tumor progression during chemo-
therapy is a clear indicator of treatment failure. Thus we believe that the exclu-
sion of these patients would have biased the survival comparisons for the
assessment of TP53 as a biomarker predicting response to treatment.
The major outcome measures were response as determined by overall
survival, tumor-associated survival, and objective tumor response.The Journal of Thoracic and CarAdditionally objective tumor response was measured in terms of a change
in the size of the tumor. Computed tomography scans were used to measure
tumor mass at initial pretreatment staging and at restaging (before surgery).
Complete remission (CR) was defined as complete absence of tumor,
confirmed by histologic investigation of the surgical specimen. Partial
responsewas defined asmajor or obvious response, expressed as aminimum
reduction of 30% in tumor mass. Progressive disease was defined as an in-
crease in tumor mass or the appearance of new peripheral lesions.
For analysis of the TP53 genotype, tumor DNA was extracted from
paraffin-embedded tissue of the diagnostic tumor biopsies. The patients’
marker status was assessed with a standardized gene-specific sequencing
kit for the p53 gene (mark53 kit; mark53 Ltd, Vienna, Austria).
Mutations in the p53 gene were reported according to the recommenda-
tions of the Human Genome Variation Society (www.hgvs.org).8
Silent mutations were rated normal.
Statistical Analysis
Continuous data are described with mean and standard deviation in
cases of normal distribution or by median, minimum, and maximum other-
wise. Differences between groups were tested by independent samples t
test in case of normal distribution and by Wilcoxon rank-sum test other-
wise. Categorical data are described with absolute and relative frequencies.
A c2 test was used to assess for group differences for binary and nominal
variables. For ordinal variables a trend c2 test was used. In case of sparse
data the Fisher exact test or exact c2 tests were used.
Surgical mortality included all deaths within 30 days after the operation
or during hospitalization.
The primary outcome measure was overall survival, tumor-associated
survival, and treatment response. Overall survival and tumor-associated sur-
vival are defined from the date of the first cycle of neoadjuvant chemotherapy
until death or last time known to be alive. Overall survival included all
deaths, independent of the cause. Median follow-up time was calculated
by Kaplan-Meier method where deaths are censored for further follow-up.
Survival probabilitieswere estimated byKaplan-Meier graphs and group dif-
ferences were assessed by log-rank test. The Cox regression model was used
to assess group differences by hazard ratios (HRs) and corresponding 95%
confidence intervals (CIs). Multiple Cox regression models were fitted to
assess the influence of TP53 on survival additional to standard prognostic
factors to evaluate if TP53 is an independent prognostic factor. However
this overfitted model cannot be seen as prognostic model for future patients.
Statistical calculations are performed with SAS (SAS Institute Inc,
Cary, NC) and SPSS (IBM-SPSS Inc, Armonk, NY). All P values are 2-
sided and P  .05 was considered significant.RESULTS
Patients
Thirty-six patients with primary operable esophageal
cancer who had received neoadjuvant treatment with fluoro-
uracil and cisplatin were evaluated for their TP53 status.
The TP53 mutation rate in the study cohort was 50% (18
out of 36). TP53 mutations are described in Table 1. Pre-
treatment patient characteristics are shown in Table 2.
At the time of evaluation, after a median follow-up of 87.4
months (7.3 years), 33 of 36 patients were dead (91.7%)
(Figure 1). Seven patients died from nontumor-related
causes: of these 3 died perioperatively due to acute respira-
tory distress syndrome, pneumonia, or anastomosis failure; 2
patients died as a result of stroke; 1 died due to sepsis; and in
1 patient the cause of death was unknown. Three patients are
still alive andwere censored between 79 and 96months. One
half of patients survived for longer than 13.9 months.diovascular Surgery c Volume 148, Number 5 2281
TABLE 1. TP53 mutations in patients with esophageal cancer
Patient no. Exon TP53 mutation*
1807 5 c.422G>A (p.Cys141Tyr)
1789 5 c.452C>G (p.Pro151Arg)
1794 5 c.469G>T (p.Val157Phe)
2047 5 c.514G>T (p.Val172Phe)
1916 6 c.569dupC (p.Pro191SerfsX18)
1811 6 c.635_636delTT (p.Phe212SerfsX3)
1804 6 c.659A>G (p.Tyr220Cys)
1797 7 c.707A>G (p.Tyr236Cys)
1837 7 c.713delG (p.Cys238LeufsX9)
1809 7 c.743G>A (p.Arg248Gln)
1833 7 c.742C>T (p.Arg248Trp)
1798 8 c.811G>A (p.Glu271Lys)
1800 8 c.818G>A (p.Arg273His)
1579 8 c.818G>A (p.Arg273His)
1805 8 c.824G>A (p.Cys275Tyr)
2048 8 c.833C>G (p.Pro278Arg)
1810 8 c.844C>T (p.Arg282Trp)
1802 8 c.916C>T (p.Arg306X)
*Reported according to Recommendations of the Human Genome Variation Society
(www.hgvs.org).8
FIGURE 1. Overall survival in patients with normal TP53 versus mutant
TP53.
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Chemotherapy
CR (2 pathologic and 1 clinical) occurred in 9% of pa-
tients (3 out of 36). The patient with clinical CR at restaging
refused to undergo surgery (Table 3). Pathologic CRTABLE 2. Pretreatment patient characteristics
Characteristic
TP53
normal
TP53
mutated Total P value
TP53 genotype 18 18 36
Sex
Male 15 15 30
Female 3 3 6 1.000
Age, y (mean  SD) 60.4  8.0 64.2  7.9 62.3  8.1 .1619
Tumor type
Adenocarcinoma 11 9 20
Squamous cell
carcinoma
7 9 16 .5023
Clinical tumor staging
T0/carcinoma in situ 0 0 0
T1 0 2 2
T2 6 5 11
T3 9 9 18 .7994
T4 0 1 1
Missing* 3 1 4
N0 7 3 10
N1 8 14 22 .1283
Missing* 3 1 4
Gx 0
G1 1 1 2
G2 6 10 16
G3 6 7 13 1.000
Missing* 5 0 5
SD, Standard deviation. *Missing values in TN staging are due to stent implantation
before computed tomography.
2282 The Journal of Thoracic and Cardiovascular Surincludes 1 patient with yT0 and 1 patient with carcinoma
in situ. All CRs occurred in patients with TP53 normal tu-
mors, whereas there was no CR observed in patients with
TP53 mutant tumors (Table 3).
Survival by TP53 Mutation
Neoadjuvant treatment with cisplatin/fluorouracil re-
sulted in a significant benefit for overall survival
(P ¼ .0304) and tumor-associated survival (P ¼ .0049) in
patients with a normal TP53 status compared with those
with a mutant TP53 status (Figures 1 and 2).
Overall survival is shown in Figure 1. Median overall sur-
vival was 8.6 months for patients with mutated TP53 and
26.2 months for patients with nonmutated TP53, which cor-
responds to an HR of 2.15 (95% CI, 1.06-4.38).
Tumor-associated survival is shown in Figure 2. Median
tumor-associated survival was 8.9 months for patients
with mutated TP53 and 34.2 months for nonmutated
patients, which corresponds to an HR of 3.01 (95% CI,
1.36-6.86).
Multiple Cox regression models were fitted to assess the
influence of TP53 on survival additional to the standard
prognostic factors shown in Table 2 to evaluate if TP53 is
an independent prognostic factor. Despite the overfit of
the model, patients with TP53 mutations still showed a
significantly higher risk for shorter overall survival
(HR, 4.075; 95% CI, 1.209-13.737; P ¼ .0235) and
tumor-associated survival (HR, 7.417; 95% CI, 1.974-
27.876; P ¼ .0030) additional to the standard prognostic
factors.
Adenocarcinoma Versus Squamous Cell Carcinoma
Sixteen cases of squamous cell carcinoma and 20 cases of
adenocarcinoma were included in our investigation. Of thegery c November 2014
TABLE 3. Posttreatment patient characteristics
Characteristic TP53 normal TP53 mutated Total P value
Pathologic tumor staging
yT0 1 0 1
Carcinoma in situ 1 0 1
yT1 3 2 5
yT2 3 4 7
yT3 9 4 13
yT4 0 0 0 .8471
Missing 1 8 9
N0 7 3 10
N1 10 7 17 .6919
Missing 1 8 9
Gx 1 0 1
G1 2 3 5
G2 8 5 13
G3 6 2 8 .6282
Missing 1 8 9
Adapted pathologic tumor staging*
Carcinoma in situ 2 0
yTIS 1 0
yT1 3 2
yT2 3 4
yT3 9 4
Adapted T4 0 8
Adapted missing 0 0 .0191
Surgery
Mean number (range) of resected lymph nodes 17 (10-43) 16 (5-28) 16 (5-43) .4598
Resection
Radical 15 9 24
R1 2 1 3
No resection 1 8 9 .0236
Reasons for no resection
Complete tumor remission/refused surgery 1 0 1
Clinical progression, poor condition 0 1 1
Inoperability due to local progression 0 4 4
Inoperable due to systemic progression 0 3 3
Nontumor-related deaths
Pneumonia 2 1 3
Other 3 1 4
Response
Complete remissiony 3 0 3
Partial remission 14 4 18
Stable disease 1 6 7
Progressive disease 0 8 8 <.0001
*For the adapted tumor staging the missing values were adapted in that the 8 patients who were nonoperable due to disease progression (all TP53 mutated) were added to pT4
(worst case) and the 1 patient who refused surgery due to clinical complete remission was added to pT0 (best case). yComplete remission included 2 pathologic and 1 clinical
complete remission: 1 patient refused to undergo surgery after experiencing clinical complete remission at restaging. Pathologic complete remission occurred in 2 patients. One
had stage yT0 and 1 showed circumscribed high grade dysplasia with focal transition to carcinoma in situ in the pathologic specimen. Both patients had negative lymph nodes.
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had adenocarcinoma. There was no difference in the fre-
quency of TP53 mutation between the 2 histologic types
(Table 2). Tumor-associated overall survival did not differ
in the 2 histologic types (P ¼ .4102). For both histologic
types, tumor-associated survival was improved in patients
with normal TP53 (adenocarcinoma P ¼ .0042; squamous
cell carcinoma P ¼ .0615).The Journal of Thoracic and CarSurgery
A transthoracic resection was performed in 13 patients,
a transhiatal resection was performed in 12 patients, and 2
patients underwent extended gastrectomy. Posttreatment
patient characteristics are shown in Table 3.
Nine patients had no curative resection. Thereforewe had
9 missing values for pathologic staging. With 9 missing
values in the calculation no statistically significantdiovascular Surgery c Volume 148, Number 5 2283
FIGURE 2. Tumor-associated survival in patients with normal TP53
versus mutant TP53.
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Sassociations were observed between pathologic T stage and
TP53 status (Table 3).
Regarding the reasons for not performing curative resec-
tion, they could be considered as informative for treatment
response: One patient refused to undergo surgery after expe-
riencing clinical CR at restaging. Eight patients presented
with disease progression after neoadjuvant chemotherapy: 4
were inoperable due to local progression (confirmed by surgi-
cal exploration), 3were inoperable due denovodistantmetas-
tases, and 1 had progressive disease and deemed unfit for
surgery.
When we take the missing values as clinically informa-
tive and adapt them in that we considered the 8 patients
without surgery due to disease progression as T4 (worst
case), and the 1 patient who refused surgery due to clinical
CR as T0 (best case), the statistical test shows a significant
association between pathologic tumor stage and TP53 mu-
tation status (P ¼ .0191).DISCUSSION
A markedly different survival after neoadjuvant chemo-
therapy was observed comparing patients with TP53 normal
and TP53 mutant esophageal cancer, suggesting a lack of
response to neoadjuvant cisplatin/fluorouracil in the popu-
lation with mutant TP53.
Overall the observed median survival (13.9 months) and
2-year survival rate (36.1%) conformed with results from 2
published clinical trials,7,9 namely the US Intergroup trial
and the British Medical Research Council trial, which had
applied comparable neoadjuvant regimens and patient
selection criteria.
Stratification by TP53marker status revealed a markedly
different survival in the 2 marker groups: TP53 normal pa-
tients showed a median overall survival of 26.2 months and2284 The Journal of Thoracic and Cardiovascular Sura 2-year overall survival rate of 55.6%, compared with 8.6
months and 16.7% in patients with mutant TP53.
There are several studies evaluating the correlation ofTP53
status and response to chemo/radio therapy in esophageal can-
cer: A recent meta-analysis comprising 1497 cases from 28
studies concluded that normal TP53 was associated with
high response to chemotherapy-based treatment in esopha-
geal cancer.10By its nature ameta-analysis is not homogenous
for treatments, patient selection, and particularly for the p53
assays (several studies used p53 immunohistochemistry).
Nevertheless the HR for pathologic major response was re-
ported to be 1.15 (95% CI, 1.06-1.25; P ¼ .001). Our study,
which is unique in that it uses for the first time a standardized,
p53-specific sequencing analysis, and thereby avoids the
possibility of missing of mutations, showed an HR for
tumor-associated survival of 3.01 (95% CI, 1.36-6.86).
Other published reports addressing the clinical significance
of p53 have been inconsistent.11,12 Methodologic limitations
such as the use of p53 immunohistochemistry or incomplete
sequencing may account for these conflicting results. For
esophageal cancer it has been explicitly shown that p53
immunohistochemistry does not correlate with response
to chemotherapy, curative resection rate, or prognosis,
whereas data from TP53 mutation analyses are more
consistent concerning the association of TP53 mutation and
poor survival.13-15 To date it is not clear if poorer prognosis
or poorer response to chemotherapy is the reason for the
survival disadvantage in patients with mutant TP53.
The objective tumor response observed in our study sug-
gests a lack of response to neoadjuvant therapy in the popu-
lation with mutant TP53. Fourteen of 18 patients with TP53
mutations had stable or progressive disease. On the other
hand, CR was observed only in patients with normal TP53.
The multiple Cox model indicated that TP53 prognosed
survival independently from established prognostic
markers. However this model is based on a small sample
size and model instability cannot be excluded. Because
TP53 showed significant effects despite these heavily over-
fitted models, this is an indicator that TP53 might be an in-
dependent prognostic factor.
Study Limitations
It should be noted that our study lacked a surgery-only
arm. Thereforewe can only speculate that TP53may be use-
ful as a predictor of response to neoadjuvant therapy.
Assessment of objective tumor response in cancer ther-
apy is a difficult issue. Comparisons of pretreatment with
posttreatment staging bear limitations that need to be
considered. The neoadjuvant setting of our study is advan-
tageous in that it permits determination of pathologic
response in resected specimens, which is considered more
accurate than imaging. But as demonstrated, patients who
cannot undergo resection due to disease progression during
chemotherapy create missing values for pathologic staging.gery c November 2014
*The P53 Adapted Neoadjuvant Chemotherapy for Operable Esophageal Cancer
(PANCHO) trial (www.clinicalTrials.gov identifier: NCT00525200; www.p53.at)
is being conducted by the p53 Research Group and has successfully recruited
168 patients with primarily resectable esophageal cancer from 2007 to 2012 at
13 centers in Austria.
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chemotherapy resulting in inoperability is very informative,
because it indicates treatment failure. Thus ignorance of
this information can bias the results because patients with
treatment failure are excluded from analysis. Therefore,
we adapted the missing values for an additional calculation
in Table 3 (adapted pathologic tumor staging), and could
demonstrate that posttreatment staging was significantly
worse for the populations with mutated TP53.
Another problem when dealing with objective tumor
response is the inaccuracy of imaging, a problem that may
be aggravated by chemotherapy.16 The Response Evalua-
tion Criteria In Solid Tumors criteria aimed to standardize
tumor measurements and response reporting.17
Availability of pathologic tumor staging in neoadjuvant
therapy studies reveals that the inaccuracy of clinical stag-
ing is still a problem and cannot be eliminated completely
even with the integration of advanced technology like endo-
scopic ultrasound and fluordeoxyglucose PET or (better
still) PET-computed tomography.
Many anticancer treatments fail to induce substantial ben-
efits. It has been said that ‘‘over the last decade, the use of
overall survival as primary endpoint has decreased signifi-
cantly in clinical trials, as has the magnitude of benefit
deemed clinically relevant.’’18 Molecular markers are ex-
pected to generate significant survival differences. Our re-
sults seem to be consistent with these expectations. In
contrast to tumor response, survival can be assessed accu-
rately and calculated to the day.19-21 Today we notice that
with the implementation of molecular markers overall
survival regains importance for demonstrating a benefit
from treatment.20 As a consequence molecular markers are
expected to raise the bar for clinical trials.
FUTURE ANALYSES
The Neoadjuvant Chemoradiation Followed by Surgery
versus Surgery Alone for Patients with Adenocarcinoma or
Squamous Cell Carcinoma of the Esophagus (CROSS) trial
probably addresses the most effective treatment for esoph-
ageal cancer to date, but the data may not be useful for
retrospective evaluation of a biomarker like TP53. In the
CROSS trial, neoadjuvant treatment consisted of weekly
carboplatin plus paclitaxel and concurrent radiotherapy.22
Carboplatin and radiation are likely to act via a p53-
controlled pathway—a hypothesis that we were able to
validate in a number of clinical studies.23-26 But
docetaxel acts differently and it is not clear if and how it
interacts with TP53.27,28 Thus, due to the combination of
these differential acting treatments in the CROSS trial,
findings may be difficult to interpret when the population
is stratified by TP53 status.29
To answer the question if and how TP53 interacts with
different classes of chemotherapy drugs in esophageal
cancer, we conducted a prospective randomized trial, theThe Journal of Thoracic and Carp53-Adjusted Neoadjuvant Chemotherapy for Potentially
Resectable Esophageal Cancer (PANCHO) trial.* The trial
was designed according to the ‘‘marker by treatment inter-
action design’’ recommended by Sargent and colleagues30
as a suitable design to answer a predictive biomarker ques-
tion. In the PANCHO trial, patients with resectable esoph-
ageal cancer were stratified on the basis of the biomarker
TP53 and subsequently randomized to different neoadju-
vant treatments (cisplatin/fluorouracil vs docetaxel mono-
therapy). Recruitment for the PANCHO trial was recently
completed; the data are awaited.CONCLUSIONS
In patients with esophageal cancer a markedly differen-
tial survival after neoadjuvant chemotherapy could be
demonstrated for the first time when comparing tumors
with normal TP53 and tumors with mutant TP53. Our re-
sults suggest a lack of response to neoadjuvant cisplatin/
fluorouracil in the population with mutant TP53. Further
studies are needed to validate our findings.References
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p53 genotyping: A fortune-teller’s crystal ball or a viable prognostic tool?Katie S. Nason, MD, MPHIdeally, predictive biomarkers with associated targeted ther-
apies would be available for individualized treatment of
esophageal cancer, optimizing outcome and minimizingchemotherapy-associated risks. Unfortunately, clinically
relevant biomarker identification for esophageal cancer
has been elusive, more often resembling predictions from
a fortune-teller’s crystal ball than proving to be valid, clin-
ically useful prognostic tools. The quest continues, howev-
er, and the p53 (TP53) gene appears promising. One of the
most frequently mutated cancer-associated genes and a crit-
ical tumor suppressor gene involved in programed cell
death,1 multiple studies show a relationship between
TP53 mutation and response to chemotherapy, including
that of esophageal cancer. A recent meta-analysis of 28
studies with 1497 patients by Zhang and colleagues2
showed high response rates to chemotherapy-based treat-
ment regimens in tumors with low p53 protein expression
or wild-type p53. Despite statistically significant findings,
however, the conclusions were limited by tremendous het-
erogeneity across studies with respect to assessment of ther-
apeutic response, chemotherapy regimens (dose and type),gery c November 2014
